Regeneron Pharmaceuticals
REGN
1,388 hedge funds and large institutions have $70.7B invested in Regeneron Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 272 funds opening new positions, 503 increasing their positions, 457 reducing their positions, and 107 closing their positions.
154% more first-time investments, than exits
New positions opened: 272 | Existing positions closed: 107
72% more call options, than puts
Call options by funds: $2.12B | Put options by funds: $1.23B
44% more capital invested
Capital invested by funds: $49B → $70.7B (+$21.7B)
29% more funds holding in top 10
Funds holding in top 10: 21 → 27 (+6)
11% more funds holding
Funds holding: 1,245 → 1,388 (+143)
10% more repeat investments, than reductions
Existing positions increased: 503 | Existing positions reduced: 457
5.04% more ownership
Funds ownership: 83.61% → 88.65% (+5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$1.65B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$778M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$567M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$446M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$261M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$493M |
| 2 |
D.E. Shaw & Co
New York
|
-$480M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$408M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$276M |
| 5 |
Two Sigma Advisers
New York
|
-$218M |
REGN Hedge Fund Activity: Q4 2025 in Review
1,388 institutional investors reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2025, worth a combined $70.7B — up 44% from $49B a quarter earlier.
Buyers outnumbered sellers: 272 funds opened new REGN positions and 107 closed out — a net gain of 165 holders — while 503 added to existing stakes and 457 trimmed.
The largest buyer was Invesco, adding an estimated $1.65B. The largest seller was Capital International Investors, exiting entirely with an estimated $493M sold.
- 1,388 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2025, up from 1,245 in Q3 2025.
- Funds reported $70.7B of Regeneron Pharmaceuticals stock for Q4 2025, up 44% quarter-over-quarter.
- 272 funds opened new Regeneron Pharmaceuticals positions in Q4 2025 and 107 closed out, a net change of +165 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2025 was Invesco, an estimated $1.65B added.
- The largest Regeneron Pharmaceuticals seller in Q4 2025 was Capital International Investors, an estimated $493M sold.
Based on aggregated 13F filings for Q4 2025.